Long-Acting Drugs Market to Reach US$ 13.3 Billion by 2033 Expands Amid Advances in Sustained Drug Delivery and Chronic Disease Management - Persistence Market Research

LONDON, June 30, 2026 /PRNewswire/ -- The global long-acting drugs market is growing steadily, expected to be valued at around US$ 7.2 billion in 2026 and projected to reach US$ 13.3 billion by 2033, with a CAGR of 8.9% in the coming years. This expansion comes from the increasing prevalence of chronic diseases, rising demand for patient-friendly therapies, and rapid innovation in sustained-release drug delivery systems. Long-acting formulations are increasingly used in oncology, diabetes, HIV, psychiatric disorders, and cardiovascular diseases, where consistent therapeutic levels are critical for long-term management.

Rising Burden of Chronic Diseases Fuels Demand for Long-Acting Therapies

The worldwide increase in chronic diseases is significantly boosting demand for long-acting drugs. Conditions such as cancer, diabetes, schizophrenia, HIV, and cardiovascular disorders require prolonged treatment regimens, where patient adherence often becomes a major challenge. Long-acting formulations address this issue by reducing dosing frequency and maintaining stable drug concentrations over weeks or months.

For instance, the World Health Organization reported nearly 20 million new cancer cases globally in 2022, while diabetes continues to affect more than 500 million people worldwide. This growing patient population is encouraging healthcare providers to adopt therapies that improve convenience and reduce relapse risks.

Long-acting injectables and polymer-based depots are increasingly used in psychiatric care, where treatment interruptions can lead to hospitalization. Similarly, HIV prevention therapies such as injectable cabotegravir have transformed adherence patterns by replacing daily oral regimens with bi-monthly dosing schedules.

Pharmaceutical companies are responding with advanced formulations that enhance bioavailability, extend therapeutic action, and minimize side effects. In 2025, investments in long-acting oncology and CNS therapies accelerated as healthcare systems prioritized improved patient outcomes and lower treatment costs.

Get a Free Sample: https://www.persistencemarketresearch.com/samples/34040

Key Highlights

• The global long-acting drugs market is projected to grow from US$ 7.2 billion in 2026 to US$ 13.3 billion by 2033, registering a CAGR of 8.9%.
• Rising prevalence of chronic diseases such as cancer, diabetes, HIV, and CNS disorders is accelerating demand for sustained-release therapies worldwide.
• North America leads the market with 41.2% share, supported by advanced healthcare infrastructure and strong pharmaceutical R&D investments.
• Asia Pacific is emerging as the fastest-growing region due to expanding healthcare access, increasing patient population, and government support for innovative therapies.
• Microsphere-Based Systems dominate delivery technology adoption because of their controlled drug release capabilities and improved patient adherence.

Technological Advancements in Drug Delivery Systems Accelerate Innovation

Innovation in drug delivery technology is another major driver of the long-acting drugs market. Pharmaceutical companies are developing advanced systems such as microspheres, liposomes, biodegradable implants, and polymer depots to deliver controlled and sustained drug release.

Microsphere-based systems remain the dominant technology because they provide precise release profiles and improve drug stability. These formulations are widely used in oncology, hormonal therapies, and central nervous system disorders due to their ability to maintain therapeutic effectiveness for extended periods.

The rise of oral long-acting biologics also represents a transformative opportunity. Technologies using permeation enhancers and protective coatings are enabling peptide-based therapies to survive gastric degradation and maintain bioavailability. Products such as oral semaglutide and next-generation GLP-1 therapies demonstrate how sustained-release technologies are expanding beyond injectables.

Manufacturers are also investing in sensor-enabled delivery systems and smart packaging solutions that improve dose tracking and patient monitoring. These innovations support adherence while helping healthcare providers optimize treatment plans through real-time data collection.

Key Highlight: Eli Lilly Advances Oral GLP-1 Innovation in 2025

• A standout event in 2025 was the advancement of Eli Lilly and Company's oral GLP-1 receptor agonist, orforglipron, following successful Phase III clinical trial results in diabetes and obesity management. According to the company, the therapy demonstrated statistically significant improvements in blood sugar control and body weight reduction across multiple late-stage studies involving adults with type 2 diabetes and obesity.
• The development highlighted growing industry interest in oral alternatives to injectable GLP-1 therapies. Eli Lilly stated that orforglipron is a once-daily oral small-molecule GLP-1 receptor agonist designed without food and water intake restrictions, differentiating it from existing oral GLP-1 treatments. In one Phase III study, the drug showed superior efficacy compared with oral semaglutide in reducing A1C and body weight.
• The innovation also reflects increasing commercial focus on expanding obesity and diabetes treatment access through convenient oral therapies. Reuters reported that Eli Lilly expected obesity trial results for orforglipron during 2025 as demand for GLP-1 therapies continued to surge globally. Additional media reports noted that the company aimed to pursue regulatory approvals following positive trial outcomes.

This development signals a broader transition toward patient-focused chronic disease therapies that prioritize ease of administration and long-term treatment adherence. The progress of oral GLP-1 medicines is expected to intensify competition within diabetes and obesity management markets, encouraging further investments in next-generation oral metabolic therapies.

Request a Customization: https://www.persistencemarketresearch.com/request-customization/34040

Segmentation Insights: Microsphere-Based Systems Lead Delivery Technology Segment with Superior Sustained-Release Performance

Microsphere-Based Systems dominate the delivery technology segment of the long-acting drugs market due to their ability to provide controlled and sustained drug release, improving therapeutic effectiveness and patient compliance. These biodegradable polymer particles gradually release active ingredients over weeks or months, significantly reducing dosing frequency in chronic disease treatments. The technology is widely used across oncology, hormonal therapies, CNS disorders, and infectious disease management because of its versatility and compatibility with injectable formulations. Microspheres also improve drug stability, bioavailability, and targeted delivery while minimizing side effects. Strong regulatory familiarity, expanding clinical adoption, and continuous advancements in biodegradable polymer technologies further strengthen their leadership position in the global long-acting drugs market.

Regional Insights: North America Leads Long-Acting Drugs Market While Asia Pacific Emerges as Fastest-Growing Regional Hub

North America holds the largest share of the long-acting drugs market, accounting for about 41.2% of global value, supported by strong pharmaceutical R&D activity, advanced healthcare infrastructure, and favorable regulatory approvals. The U.S. dominates regional demand due to increasing adoption of long-acting injectables in oncology, diabetes, schizophrenia, and HIV therapies. FDA approvals for sustained-release formulations and strong reimbursement policies continue to strengthen market expansion.

Asia Pacific is the fastest-growing region. China and India are leading regional growth due to rising chronic disease prevalence, improving healthcare access, and expanding pharmaceutical manufacturing capabilities. Government healthcare initiatives and growing investments in drug delivery innovation are encouraging adoption of long-acting therapies across large patient populations.

Europe follows with strong growth supported by aging populations, increasing clinical trial activity, and investments in advanced drug delivery technologies. Regulatory support from the European Medicines Agency and funding initiatives focused on innovative therapeutics continue to strengthen the region's position.

Key Players and Business Strategies

Leading players include Eli Lilly and Company, ViiV Healthcare, Johnson & Johnson, Novartis AG, and AstraZeneca plc.

• Eli Lilly is expanding its metabolic disease portfolio through advanced oral GLP-1 therapies and sustained-release drug delivery innovation targeting diabetes and obesity treatment.
• ViiV Healthcare focuses on long-acting HIV prevention and treatment solutions, strengthening its position through injectable therapies that improve patient adherence and reduce dosing frequency.
• Johnson & Johnson continues investing in long-acting psychiatric therapies, particularly injectable antipsychotics designed to improve treatment persistence in schizophrenia management.
• Novartis is strengthening oncology-focused sustained-release formulations and precision medicine initiatives to improve therapeutic effectiveness across chronic conditions.
• AstraZeneca is investing in biologic delivery technologies and strategic partnerships aimed at enhancing long-term treatment outcomes in cardiovascular and metabolic diseases.

Strategies across the industry emphasize advanced delivery technologies, expansion of chronic disease portfolios, patient-centric formulations, and partnerships supporting innovation in sustained-release therapeutics.

Buy Now: https://www.persistencemarketresearch.com/checkout/34040

Market Segmentation

By Delivery Technology

• Liposome-Based Systems
• Microsphere-Based Systems
• Polymer-Based Depots
• In-Situ Forming Gels
• Nanoparticle-based systems

By Route of Administration

• Injectable
• Implant
• Oral

By Therapeutic Area

• Cancer
• Central Nervous System (CNS) Disorders
• Hormone Disorders
• Infectious Diseases
• Pain Management
• Contraception

By Material Used

• Polymer
• Non-Polymer

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics

By Region

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East and Africa

Get More Insights — Related Healthcare Market Reports:

Sterile Injectable Drugs Market by Product Type (Large, Small Molecule), Drug Class (Monoclonal Antibodies, Cytokines, Insulin), Administration Route (Intradermal, Intramuscular), Dosage Form, and Regional Analysis for 2025 – 2032

U.S. Antipsychotic Drugs Market by Disease (Schizophrenia, Bipolar Disorder, Others), Therapeutic Class (First Generation, Second Generation, Third Generation), Distribution Channel (Hospital Pharmacies, Others), and Zone Analysis 2026 – 2033

Medical Marijuana Market by Product Type (Flowers, Edibles, Concentrates, Others), Application (Chronic Pain, Cancer, Mental Disorders, Others), End-user (Research & Development, Pharmaceutical), and Regional Analysis for 2026 – 2033

Injectable Drug Delivery Market by Device Type (Conventional Injection Devices, Prefilled Syringes, Auto-Injectors, Others), Route of Administration (Intravenous, Intramuscular, Subcutaneous), End-user (Hospitals & Clinics, Home Care Settings, Others), and Regional Analysis for 2026 – 2033

Metered Dose Inhalers Market by Inhaler Type (Standard Metered Dose Inhalers, Others), Disease Type (Asthma, COPD, Others), Medication Type (Reliever Inhalers, Preventive Inhalers, Combination Therapy Inhalers), and Regional Analysis for 2026 – 2033

Diabetic Nephropathy Market by Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers, SGLT2 Inhibitors, Others), Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Others), and Regional Analysis for 2026 – 2033

Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class (Opioid Antagonists, Opioid Agonists and Partial Agonists), Indication (Pain Management, Opioid Withdrawal/Opioid Use Disorder (OUD), Others), and Regional Analysis for 2026 – 2033

Giant Cell Arteritis Treatment Market by Treatment Type (Corticosteroid Therapy, Immunosuppressive Agents, Anticoagulants, and Monoclonal Antibodies), Route of Administration (Oral, Intravenous, and Subcutaneous), and Regional Analysis for 2026 – 2033

Ciprofloxacin Market by Dosage Form (Powder, Suspension, Tablet, Eye drops, Intravenous preparation) Application (Urinary tract infections, Lower respiratory infections, Nosocomial pneumonia, Others), and Regional Analysis for 2026 – 2033

Drug-Resistant Tuberculosis Market by Drug Class (Amoxicillin/Clavulanate, Bedaquiline, Carbapenems with Clavulanic Acid, Clofazimine, Others), Disease Type (Active TB, Latent TB), Treatment Type, Distribution Channel, and Regional Analysis for 2026 - 2033

About Persistence Market Research:

At Persistence Market Research, we are pioneers in Market Research and Consulting, bringing you the most dynamic insights into market trends, consumer behaviours, and competitive intelligence! For over a decade, we've been at the forefront of delivering game-changing analytics and research that drive businesses toward growth.

Our extensive market report database is a go-to resource for Fortune 500 companies, savvy business investors, media and entertainment channels, and academic institutions, empowering them to navigate the global and regional business landscape with confidence. With thousands of statistics and in-depth analyses covering over 20 diverse industries across 25 major countries, we provide the insights you need to succeed in today's competitive environment.

Contact
Ankush Nikam
Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ
+44 203-837-5656
United Kingdom
USA Phone - +1 646-878-6329
Email: sales@persistencemarketresearch.com

Logo: https://mma.prnewswire.com/media/2876873/Persistence_Market_Research_Logo.jpg